Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Results
Phase 2
This trial looked at azacitidine and vorinostat for people who can’t have intensive treatment for acute myeloid leukaemia or high risk myelodysplastic syndrome.
Recruitment start: 25 September 2012
Recruitment end: 31 August 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Charles Craddock
Bloodwise Trials Acceleration Programme (TAP)
Celgene
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
Merck
NIHR Clinical Research Network: Cancer
Oxford Partnership Comprehensive Biomedical Research Centre
University of Birmingham; Cancer Research UK Clinical Trials Unit
Last reviewed: 19 April 2018
CRUK internal database number: 9307
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
